{"product_id":"bio-bcg-matrix","title":"(BIO) Bio-Rad Laboratories, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Bio-Rad Laboratories, Inc. BCG Matrix is a ready-made strategic tool used to assess the company’s products or business units across Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDroplet Digital PCR QX200 and QX600\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBio-Rad Laboratories, Inc.’s Droplet Digital PCR QX200 and QX600 sit in the Stars quadrant: Bio-Rad remains a top name in digital PCR, and the market keeps growing for absolute quantification and rare-target detection. The systems support up to about 20,000 droplets per sample, while QX600 adds six-plex capability, lifting strategic value. They also drive high-margin reagent pull-through after each instrument sale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eddPCR assay kits and consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn fiscal 2025, Bio-Rad Laboratories, Inc. kept growing ddPCR pull-through as each system sale adds recurring reagent demand, so ddPCR assay kits and consumables fit a Star. The category scales with the installed base and repeat use, which supports steady, high-margin revenue after placement. In Bio-Rad Laboratories, Inc. 2025 results, recurring lab demand stayed central to the model, and that is the profit engine here.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBio-Plex multiplex immunoassay systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBio-Plex multiplex immunoassay systems can measure up to 100 analytes in a single sample, which fits biomarker discovery and multi-analyte research well. Multiplex testing keeps growing in translational and academic labs because it saves sample volume and speeds data generation. Bio-Rad’s installed-base support and specialty positioning help keep reagent pull-through strong, which supports Star status.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBiopharma workflow tools for protein purification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBiopharma workflow tools for protein purification fit Bio-Rad Laboratories, Inc. as a Star: biologics growth keeps lifting demand for purification and characterization, and Bio-Rad sells chromatography and workflow products that ride that need.\u003c\/p\u003e\n\u003cp\u003eThe segment benefits from premium consumables pull-through, since each run needs resins, columns, and related kits, so recurring revenue can scale with biologics output.\u003c\/p\u003e\n\u003cp\u003eBio-Rad’s Life Science segment remains tied to this trend, with 2025 demand supported by bioprocessing and QC use cases rather than one-off instrument sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBiologics growth supports steady demand.\u003c\/li\u003e\n\u003cli\u003eChromatography drives recurring consumables use.\u003c\/li\u003e\n\u003cli\u003eWorkflow tools support premium pricing.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDigital biology research platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBio-Rad Laboratories, Inc.’s digital biology platforms are a Star because they bundle instruments, assays, and workflow reagents, so lab adoption can lift repeat sales. In 2025, Bio-Rad Laboratories, Inc. generated about $2.56 billion in net sales, showing a base big enough to fund this growth bet.\u003c\/p\u003e\n\u003cp\u003eThe stack is sticky: once a lab installs the platform, it tends to keep buying consumables and upgrades, which supports margin over time. Bio-Rad Laboratories, Inc. also serves a large global life science market, and that helps the digital biology mix scale as customers add more automated and data-linked workflows.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePlatform sales grow with lab usage\u003c\/li\u003e\n\u003cli\u003eConsumables support recurring revenue\u003c\/li\u003e\n\u003cli\u003e2025 net sales: about $2.56 billion\u003c\/li\u003e\n\u003cli\u003eBest fit for high-growth, high-share Star\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBio-Rad’s Growth Engines: ddPCR and Bio-Plex Keep Reagents Flowing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBio-Rad Laboratories, Inc.’s Stars are ddPCR, Bio-Plex, and biopharma workflow tools because they pair strong growth with sticky consumable pull-through. In fiscal 2025, Bio-Rad Laboratories, Inc. posted about $2.56 billion in net sales, and the installed base keeps driving repeat reagent demand.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003cth\u003e2025 note\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eddPCR\u003c\/td\u003e\n\u003ctd\u003eHigh growth\u003c\/td\u003e\n\u003ctd\u003eRecurring reagents\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBio-Plex\u003c\/td\u003e\n\u003ctd\u003e100-analyte multiplexing\u003c\/td\u003e\n\u003ctd\u003eStrong pull-through\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eBio-Rad’s BCG Matrix maps its diagnostics and life science units to guide invest, hold, or divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page Bio-Rad Laboratories BCG Matrix that quickly spots winners and laggards for faster portfolio decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a traceable source trail for Bio-Rad Laboratories, Inc., boosting credibility and helping decision-makers verify assumptions fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHbA1c testing on VARIANT II Turbo and D-10\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBio-Rad Laboratories, Inc.'s HbA1c testing on VARIANT II Turbo and D-10 is a classic Cash Cow: diabetes monitoring is mature, but the installed base keeps reagent pull-through steady. HbA1c tracks the prior 2-3 months of glucose, so labs run it again and again, which supports recurring, high-margin sales even in low-growth markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmunohematology systems for blood typing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBio-Rad Laboratories, Inc.’s immunohematology blood-typing business fits Cash Cows because transfusion testing is a tightly regulated, replacement-driven market with sticky lab placements. Its systems and reagents are embedded in hospital and reference labs, so revenue keeps coming from repeat consumables rather than heavy new capex. In Bio-Rad Laboratories, Inc.’s FY2025 mix, this type of installed-base model supports steady cash flow with limited growth spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality control and calibration products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQuality control and calibration products are a Cash Cow for Bio-Rad Laboratories, Inc. Clinical labs buy them again and again to keep analyzers accurate and meet CAP\/CLIA rules, so demand tracks routine test volume, not one-time installs. This makes the franchise steady and margin-friendly, with recurring revenue from a mature market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eElectrophoresis consumables and blotting reagents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eElectrophoresis consumables and blotting reagents are classic cash cows for Bio-Rad Laboratories, Inc.: they serve a wide installed base, sell in repeat cycles, and face low switching once labs standardize workflows. Bio-Rad’s fiscal 2025 net sales were about $2.6 billion, so these steady, replenishment-led products help support reliable cash flow even without fast growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroad installed base\u003c\/li\u003e\n\u003cli\u003eFrequent repeat orders\u003c\/li\u003e\n\u003cli\u003eLow growth, strong retention\u003c\/li\u003e\n\u003cli\u003eSteady cash generation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProtein assay reagents and standard lab chemicals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBio-Rad Laboratories, Inc.'s protein assay reagents and standard lab chemicals fit the Cash Cows bucket: they are used in daily lab workflows, face a mature and crowded market, and still benefit from a sticky installed base. These products usually generate steady cash rather than fast growth, helping fund Bio-Rad's higher-growth bets. The value here is durability, not expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh routine use\u003c\/li\u003e\n\u003cli\u003eStable, recurring cash flow\u003c\/li\u003e\n\u003cli\u003eLow growth, strong retention\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBio-Rad’s Cash Cows Keep Repeating Revenue Coming\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBio-Rad Laboratories, Inc.'s Cash Cows are mature, repeat-use products that keep money coming in from installed lab systems. FY2025 net sales were about $2.6 billion, and these franchises lean on recurring consumables, not heavy new hardware sales. HbA1c, blood typing, QC, and electrophoresis are stable because labs reorder them often. The cash comes from routine use and sticky placements.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash Cow\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHbA1c\u003c\/td\u003e\n\u003ctd\u003eRepeat reagent pull-through\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBlood typing\u003c\/td\u003e\n\u003ctd\u003eSticky installed base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQC and calibration\u003c\/td\u003e\n\u003ctd\u003eRecurring compliance demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eElectrophoresis\u003c\/td\u003e\n\u003ctd\u003eHigh repeat consumable use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eBio-Rad Laboratories, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Bio-Rad Laboratories, Inc. BCG Matrix report you’ll receive after purchase. The final file is the same fully formatted document—no mockups, no watermarks, and no hidden changes. Once purchased, it’s ready for immediate download, use, and presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy slab-gel electrophoresis hardware\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBio-Rad Laboratories, Inc.'s legacy slab-gel electrophoresis hardware fits the Dogs bucket: it serves a mature niche with slow replacement demand and little room to scale. Buyers are shifting to automated, digital workflows, so older manual formats keep losing share. With Bio-Rad Laboratories, Inc. generating about $2.6 billion of revenue in 2024, this hardware line looks low-growth and weak on expansion potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOlder standalone thermal cyclers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOlder standalone thermal cyclers fit Dogs: basic PCR tools sit in a crowded, price-sensitive market, while newer molecular platforms pull spend to digital PCR and higher-throughput systems. Bio-Rad Laboratories, Inc.'s 2025 mix still shows stronger demand in advanced workflows than in legacy hardware, so these units have low growth and weak differentiation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-end imaging and documentation systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBio-Rad Laboratories, Inc.’s low-end imaging and documentation systems fit the Dogs box: basic lab imaging is now commoditized, so pricing stays under pressure and margins stay thin. In Bio-Rad Laboratories, Inc.’s 2025 mix, these mature tools are unlikely to justify major new capital, especially versus higher-return life science platforms. They usually get maintenance funding, not growth spend, unless a clear replacement cycle opens up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCommodity food-testing assay lines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCommodity food-testing assay lines fit Bio-Rad Laboratories, Inc. as a \"Cash Cow\": food safety demand stays steady, but mature formats face heavy competition and slower growth than digital molecular workflows. In fiscal 2025, Bio-Rad Laboratories, Inc. reported about $2.57 billion in net sales, and this kind of line can absorb R\u0026amp;D and sales spend without building clear share gains.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable demand, weak growth\u003c\/li\u003e\n\u003cli\u003eHigh competition, low differentiation\u003c\/li\u003e\n\u003cli\u003eResource drag versus molecular assays\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSmall accessory hardware with limited scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSmall accessory hardware fits Bio-Rad Laboratories, Inc.’s Dogs bucket because these add-ons have low ticket sizes and little strategic pull. Bio-Rad’s 2025 net sales were about $2.56 billion, but accessories are not a main growth engine; they mostly support core systems and lab workflows. In BCG terms, they act like low-share, low-growth fillers, so capital use should stay tight.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow price, low scale\u003c\/li\u003e\n\u003cli\u003eAdd-on value, not growth\u003c\/li\u003e\n\u003cli\u003eKeep inventory lean\u003c\/li\u003e\n\u003cli\u003ePrioritize core platforms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBio-Rad’s Legacy Tools Are Low-Growth Dogs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBio-Rad Laboratories, Inc.’s Dogs are legacy tools with flat demand and weak pricing power. By fiscal 2025, net sales were about $2.57 billion, but these lines still lag higher-growth digital PCR and automated workflows. They need only maintenance spending, not heavy capital, unless a clear replacement cycle appears.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003cth\u003e2025 view\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy tools\u003c\/td\u003e\n\u003ctd\u003eLow growth\u003c\/td\u003e\n\u003ctd\u003eDogs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet sales\u003c\/td\u003e\n\u003ctd\u003eScale\u003c\/td\u003e\n\u003ctd\u003e$2.57B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpend\u003c\/td\u003e\n\u003ctd\u003eCapital use\u003c\/td\u003e\n\u003ctd\u003eLean\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSingle-cell analysis workflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSingle-cell analysis workflows fit a Question Mark: the market is growing fast, but adoption is still early and crowded. Bio-Rad Laboratories, Inc. has a real presence, yet it needs more scale, platform wins, and workflow stickiness to turn this into a stronger 2025-2026 growth engine. If Bio-Rad does not keep investing in single-cell tools and consumables, the category can stay niche instead of becoming a material profit pool.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNGS sample prep and QC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNext-generation sequencing sample prep and QC sits in a high-growth field: Bio-Rad Laboratories, Inc. reported fiscal 2025 revenue of about $2.6 billion, while its life science segment benefited from growing demand in research tools. Bio-Rad has useful adjacent products, but it is not a category leader in sequencing platforms. That makes this a Question Mark: the market is expanding, but share is still building.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical molecular diagnostics beyond HbA1c\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical molecular diagnostics beyond HbA1c is a Question Mark for Bio-Rad Laboratories, Inc. because labs keep broadening molecular panels, but Bio-Rad still leads more clearly in diabetes and transfusion than in this wider niche. In 2025, Bio-Rad posted about $2.6 billion in sales, and this segment likely needs heavy R\u0026amp;D and commercial spend to win share. That makes it a high-growth, high-investment bet with uncertain payoff.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBioprocess analytics software\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioprocess analytics software fits a Question Mark because biomanufacturing demand is rising in biologics and cell therapies, but Bio-Rad Laboratories, Inc. still has a smaller footprint here than in its core diagnostics. The category can scale fast through recurring software and data workflows, yet Bio-Rad Laboratories, Inc. has not built the same market power it holds in PCR and quality control tools.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eHigh-growth biomanufacturing use case.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eSoftware scales well, but share is thin.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eNeeds more investment to win share.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLab automation and connected workflow tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLab automation is a Question Mark for Bio-Rad Laboratories, Inc.: demand is rising in research and clinical labs, but share is still unclear in a crowded market. The global lab automation market was estimated at about $7B in 2025 and is growing at high-single-digit rates, so the pool is real. But winning needs steady R\u0026amp;D spend and tighter integration across instruments, software, and consumables.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrowing demand, uncertain share\u003c\/li\u003e\n\u003cli\u003eCrowded field, tough switching costs\u003c\/li\u003e\n\u003cli\u003eNeeds capital and product integration\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBio-Rad’s Growth Bets: Big Potential, Still Early\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBio-Rad Laboratories, Inc. Question Marks are growth niches with weak share: single-cell analysis, next-gen sequencing sample prep, broader molecular diagnostics, bioprocess analytics software, and lab automation. In fiscal 2025, Bio-Rad Laboratories, Inc. generated about $2.6 billion in revenue, so these bets matter but still need more scale and R\u0026amp;D to move from promise to profit.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSingle-cell\u003c\/td\u003e\n\u003ctd\u003eHigh growth, early adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSequencing prep\u003c\/td\u003e\n\u003ctd\u003eGrowing market, low share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab automation\u003c\/td\u003e\n\u003ctd\u003e~$7B market in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234147770633,"sku":"bio-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/bio-bcg-matrix.webp?v=1785713029","url":"https:\/\/dcfanalyst.com\/products\/bio-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}